Moderna Aktie
| 28,15USD | 3,43USD | 13,88% | 
WKN DE: A2N9D9 / ISIN: US60770K1079
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 1 300 | 2 700 | 3 900 | 5 600 | 5 800 | 
| Umsatz pro Mitarbeiter in Mio. EUR | 0,62 | 6,82 | 4,90 | 1,22 | 0,56 | 
Bilanz (in Mio. USD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 6 298 | 16 071 | 13 431 | 10 325 | 8 099 | 
| Summe Anlagevermögen | 1 039 | 8 798 | 12 656 | 8 101 | 6 043 | 
| Summe Aktiva | 7 337 | 24 869 | 26 087 | 18 426 | 14 142 | 
Bilanz (in Mio. USD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 4 775 | 10 724 | 6 964 | 4 572 | 3 241 | 
| Summe Eigenkapital | 2 561 | 14 145 | 19 123 | 13 854 | 10 901 | 
| Summe Passiva | 7 337 | 24 869 | 26 087 | 18 426 | 14 142 | 
Adresse
| 325 Binney Street, 02142 Cambridge | |
| Telefon | +1 (617) 714-6500 | 
| Internet | http://www.modernatx.com | 
Management
| Charbel Haber Senior Vice President-Regulatory Science | 
| David Mark Rubenstein Independent Director | 
| Elizabeth E. Tallett Independent Director | 
| Elizabeth G. Nabel Independent Director | 
| Francois Nader Independent Director | 
| Jacqueline Miller Chief Medical Officer | 
| James M. Mock Chief Financial Officer | 
| Jerh Collins Chief Technical Operations & Quality Officer | 
| Lavina A. Talukdar Senior Vice President & Head-Investor Relations | 
| Noubar B. Afeyan Chairman | 
| Paul L. Sagan Independent Director | 
| Rose Loughlin Executive Vice President-Research | 
| Sandra J. Horning Independent Director | 
| Shah Abbas Hussain Independent Director | 
| Shannon Thyme Klinger Secretary & Chief Legal Officer | 
| Stephen Hoge President | 
| Stéphane Bancel Chief Executive Officer & Director | 
| Tracey Franklin Chief People & Digital Technology Officer | 
 
									 
									 
								